TACROLIMUS FOR SUB EPITHELIAL INFILTRATES AFTER ADENOVIRAL KERATOCONJUNCTIVITIS

Journal of Cornea and External Disease: 

Purpose of this study is to describe the use of topical 0.03% tacrolimus in patients with symptomatic corneal subepithelial infiltrates (SEIs) secondary to adenoviral keratoconjunctivitis (AK) that were resistant to tapering of corticosteroid eye drops. Topical 0.03% tacrolimus seemed to be an effective corticosteroid–sparing agent for the treatment of SEIs after AK.